226 related articles for article (PubMed ID: 33244799)
21. Design, synthesis, and biological evaluation of new pyrazoloquinazoline derivatives as dual COX-2/5-LOX inhibitors.
Shaaban MA; Kamal AM; Faggal SI; Farag NA; Aborehab NM; Elsahar AE; Mohamed KO
Arch Pharm (Weinheim); 2020 Nov; 353(11):e2000027. PubMed ID: 32696514
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors.
Arfaie S; Zarghi A
Eur J Med Chem; 2010 Sep; 45(9):4013-7. PubMed ID: 20691338
[TBL] [Abstract][Full Text] [Related]
23. Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, In Vitro, and In Silico Studies.
Ali M; Khan M; Zaman K; Wadood A; Iqbal M; Alam A; Shah S; Ashfaq Ur Rehman ; Yousaf M; Rafique R; Khan KM
Med Chem; 2021; 17(8):903-912. PubMed ID: 32525781
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898
[TBL] [Abstract][Full Text] [Related]
25. Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.
Kassab SE; Khedr MA; Ali HI; Abdalla MM
Eur J Med Chem; 2017 Dec; 141():306-321. PubMed ID: 29031075
[TBL] [Abstract][Full Text] [Related]
26. Chalcones bearing nitrogen-containing heterocyclics as multi-targeted inhibitors: Design, synthesis, biological evaluation and molecular docking studies.
Sıcak Y; Kekeçmuhammed H; Karaküçük-İyidoğan A; Taşkın-Tok T; Oruç-Emre EE; Öztürk M
J Mol Recognit; 2023 Jul; 36(7):e3020. PubMed ID: 37092742
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.
Grover J; Kumar V; Sobhia ME; Jachak SM
Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R; Azizi E; Daraie B; Hedayati M; Dadrass OG
Bioorg Med Chem; 2009 Jul; 17(14):5312-7. PubMed ID: 19560931
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies.
El-Azab AS; Abdel-Aziz AA; Abou-Zeid LA; El-Husseiny WM; El Morsy AM; El-Gendy MA; El-Sayed MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):989-998. PubMed ID: 29806488
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.
Irannejad H; Kebriaieezadeh A; Zarghi A; Montazer-Sadegh F; Shafiee A; Assadieskandar A; Amini M
Bioorg Med Chem; 2014 Jan; 22(2):865-73. PubMed ID: 24361187
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis and Biological Evaluation of New N-Acyl Hydrazones with a Methyl Sulfonyl Moiety as Selective COX-2 Inhibitors.
Osmaniye D; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Chem Biodivers; 2021 Nov; 18(11):e2100521. PubMed ID: 34411436
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies.
Alfayomy AM; Abdel-Aziz SA; Marzouk AA; Shaykoon MSA; Narumi A; Konno H; Abou-Seri SM; Ragab FAF
Bioorg Chem; 2021 Mar; 108():104555. PubMed ID: 33376011
[TBL] [Abstract][Full Text] [Related]
33. A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis.
Consalvi S; Poce G; Ragno R; Sabatino M; La Motta C; Sartini S; Calderone V; Martelli A; Ghelardini C; Di Cesare Mannelli L; Biava M
ChemMedChem; 2016 Aug; 11(16):1804-11. PubMed ID: 27229194
[TBL] [Abstract][Full Text] [Related]
34. Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffold.
Bakr RB; Ghoneim AA; Azouz AA
Bioorg Chem; 2019 Jul; 88():102964. PubMed ID: 31075742
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of new pyrazino[1,2-a]benzimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors.
Azami Movahed M; Daraei B; Shahosseini S; Esfahanizadeh M; Zarghi A
Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800265. PubMed ID: 30561073
[TBL] [Abstract][Full Text] [Related]
37. Design & synthesis of novel oxazolone & triazinone derivatives and their biological evaluation as COX-2 inhibitors.
Mohamed LW; El-Badry OM; El-Ansary AK; Ismael A
Bioorg Chem; 2017 Jun; 72():308-314. PubMed ID: 28500957
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of 1,3-diarylprop-2-en-1-ones : a novel class of cyclooxygenase-2 inhibitors.
Zarghi A; Arfaee S; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Apr; 14(8):2600-5. PubMed ID: 16356730
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors.
Hammuda A; Shalaby R; Rovida S; Edmondson DE; Binda C; Khalil A
Eur J Med Chem; 2016 May; 114():162-9. PubMed ID: 26974383
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
Tietz O; Dzandzi J; Bhardwaj A; Valliant JF; Wuest F
Bioorg Med Chem Lett; 2016 Mar; 26(6):1516-1520. PubMed ID: 26898334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
